Levodopa-induced dyskinesias in the absence of nigrostriatal degeneration

Movement Disorders

Volumn 28, Issue 8, 2013, Pages 1023-1024

  Bézard, Erwan ^a,b   Olanow, C Warren ^c   Obeso, José A ^d  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b CNRS   (France)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA; TYROSINE 3 MONOOXYGENASE;

DISEASE SEVERITY; DOPAMINE RELEASE; DOPAMINERGIC ACTIVITY; DOPAMINERGIC NERVE CELL; DRUG INDUCED DISEASE; DYSKINESIA; EDITORIAL; HUMAN; INTRACELLULAR SIGNALING; PARKINSONISM; PRIORITY JOURNAL; STRIATONIGRAL DEGENERATION; TREATMENT RESPONSE;

DOPAMINE AGENTS; DYSKINESIA, DRUG-INDUCED; DYSTONIC DISORDERS; HUMANS; LEVODOPA;

EID: 84881556908     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25533     Document Type: Editorial

References (16)

1. Cotzias GC, Papavasiliou PS, Gellene R. Modification of Parkinsonism-chronic treatment with L-dopa. N Engl J Med 1969;280:337-345.
2. Bezard E, Brotchie JM, Gross CE. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat Rev Neurosci 2001;2:577-588.
3. Jenner P. Molecular mechanisms of L-DOPA-induced dyskinesia. Nat Rev Neurosci 2008;9:665-677.
4. Prashanth LK, Fox S, Meissner WG. L-dopa-induced dyskinesia-clinical presentation, genetics, and treatment. Int Rev Neurobiol 2011;98:31-54.
5. Olanow CW, Obeso JA, Stocchi F. Continuous dopamine receptor stimulation in the treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol 2006;5:677-687.
6. Olanow CW, Kieburtz K, Rascol O, et al.; Stalevo Reduction in Dyskinesia Evaluation in Parkinson's Disease (STRIDE-PD) Investigators. Factors predictive of the development of levodopa-induced dyskinesia and wearing-off in Parkinson's disease [published online ahead of print 29 April 2013]. Mov Disord 2013.
7. Pons R, Syrengelas D, Youroukos S, et al. Levodopa-induced dyskinesias in tyrosine hydroxylase deficiency. Mov Disord 2013;28:1058-1063.
8. Carta M, Bezard E. Contribution of pre-synaptic mechanisms to L-DOPA-induced dyskinesia. Neuroscience 2011;198:245-251.
9. Hwang WJ, Calne DB, Tsui JK, de la Fuente-Fernandez R. The long-term response to levodopa in dopa-responsive dystonia. Parkinsonism Relat Disord 2001;8:1-5.
10. Politis M, Oertel WH, Wu K, et al. Graft-induced dyskinesias in Parkinson's disease: high striatal serotonin/dopamine transporter ratio. Mov Disord 2011;26:1997-2003.
11. Shin E, Garcia J, Winkler C, Bjorklund A, Carta M. Serotonergic and dopaminergic mechanisms in graft-induced dyskinesia in a rat model of Parkinson's disease. Neurobiol Dis 2012;47:393-406.
12. Chuhma N, Choi WY, Mingote S, Rayport S. Dopamine neuron glutamate cotransmission: frequency-dependent modulation in the mesoventromedial projection. Neuroscience 2009;164:1068-1083.
13. Rayport S. Glutamate is a cotransmitter in ventral midbrain dopamine neurons. Parkinsonism Relat Disord 2001;7:261-264.
14. Seroogy KB, Lundgren KH, Tran TM, Guthrie KM, Isackson PJ, Gall CM. Dopaminergic neurons in rat ventral midbrain express brain-derived neurotrophic factor and neurotrophin-3 mRNAs. J Comp Neurol 1994;342:321-334.
15. Guillin O, Diaz J, Carroll P, Griffon N, Schwartz JC, Sokoloff P. BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization. Nature 2001;411:86-89.
16. Guillin O, Griffon N, Bezard E, et al. Brain-derived neurotrophic factor controls dopamine D3 receptor expression: therapeutic implications in Parkinson's disease. Eur J Pharmacol 2003;480(1-3):89-95.